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1CHAPTER I
INTRODUCTION
BACKGROUND
Endodontic therapy is widely thought of as being a painful experience (1).  When
most individuals seek root canal therapy, pain is already present.  A significant
relationship exists between pre-endodontic and post-endodontic pain.  Patients with
severe preoperative pain tend to have more severe operative and postoperative pain than
patients with mild or no preoperative pain (2).  Ideally, root canal therapy will eliminate
post-endodontic pain but occasionally analgesics are needed to diminish the pain.
Inflammation is initiated by histamine, bradykinin, and prostaglandins (3). 
Prostaglandins increase vascular permeability, raise chemotactic activity, induce fever,
and increase sensitivity of pain receptors to other active inflammatory mediators (4). 
Endodontic therapy produces local trauma and subsequent inflammation.  Prostaglandins
play a role in inflammation and may have a role in pain formation following endodontic
therapy.
Nonsteroidal anti-inflammatory drugs inhibit prostaglandin synthesis by
decreasing the activity of the enzyme, cyclo-oxygenase (5).  In 1991, researchers
discovered that the cyclo-oxygenase enzyme existed as two separate entities; Cox-1 and
Cox-2.  Cox-1 synthesizes protective prostaglandins, which preserve the integrity of the
2stomach lining and maintain normal renal function in a compromised kidney.  Cox-2 is
induced by pro-inflammatory cytokines and growth factors, which implies that Cox-2
plays a role in both inflammation and control of cell growth (6).  The discovery of Cox-2
has made it possible for researchers to design drugs that reduce inflammation without
removing the protective prostaglandins of the stomach and kidney.   
Oral surgery models have shown preoperative administration of the nonsteroidal
anti-inflammatory drugs ibuprofen or flurbiprofen suppress postoperative pain more
effectively than a placebo, acetaminophen, or acetaminophen plus oxycodone (7,8). 
Administration of a nonsteroidal anti-inflammatory drug prior to root canal therapy will
interfere with the inflammatory process before it begins; therefore, decreasing
postoperative pain.
Etodolac is a nonsteroidal anti-inflammatory drug that has been proven to be an
effective analgesic for rheumatoid arthritis (9,10) and post-operative pain management in
oral surgery models (11,12).  Etodolac has also been proven to have a high affinity to
block the Cox-2 enzyme (13,14).  The ability of etodolac to control post-endodontic pain,
when administered prophylactically has not been analyzed.  The goal of this study is to
determine if prophylactic etodolac will significantly reduce post-endodontic pain, when
compared to prophylactic ibuprofen, and when compared to a placebo.
STATEMENT OF PROBLEM
Etodolac possesses a high affinity to block the Cox-2 enzyme, but will
prophylactic etodolac significantly reduce post-endodontic pain, when compared to
3ibuprofen, and a placebo?
SIGNIFICANCE OF STUDY
After conventional root canal therapy, post-endodontic pain may occur.  If
prophylactic etodolac can significantly reduce post-endodontic pain, perhaps it should be
implemented in the everyday protocol for root canal therapy.
HYPOTHESIS
The two hypotheses of this study are:
1. Prophylactic etodolac will significantly reduce post-endodontic pain
when compared to ibuprofen and when compared to a placebo.
2. Prophylactic etodolac will significantly reduce post-endodontic pain
regardless of the pulpal or periapical diagnosis. 
OPERATIONAL DEFINITIONS
The following terms are defined for clarification:
Post-endodontic pain: Any pain that is perceived by the patient after root
canal therapy (cleaning/shaping and/or obturation).
Etodolac: Nonsteroidal anti-inflammatory agent, which inhibits
prostaglandin synthesis by decreasing the activity of the enzyme, cyclo-
oxygenase, specifically Cox-2.  The recommended dosage for acute pain is
200-400 mg every 6-8 hours, with the maximum daily dose being 
41200 mg.  Onset of action is 30 minutes.  Duration of analgesic effect is 4-
6 hours.
Ibuprofen:  Nonsteroidal anti-inflammatory agent, which inhibits
prostaglandin synthesis by decreasing the activity of the enzyme, cyclo-
oxygenase, both Cox-1 and Cox-2.  The recommended dosage for acute
pain is 400-800 mg 3-4 times a day, with the maximum daily dose being
3200 mg.  Onset of action is 30-60 minutes.  Duration of analgesic effect
is 4-6 hours.
Prophylactic Medication: Oral administration of a medication prior to
root canal therapy.  
Visual Analog Scale: A one-hundred millimeter horizontal line used to
measure the patients perceived pain.  Zero is the left extreme and it equals,
“No pain.”  One-hundred is the right extreme and it equals, “Pain so
severe you can’t stand it.”
Pulpal and Periapical Diagnosis:  Determined for each patient by
collecting data from the clinical exam and applying it to the flow charts in
Appendix E.
ASSUMPTIONS
The only assumption in this study is that all endodontically treated teeth
commonly produce post-endodontic pain at some level.
5LIMITATIONS
The following limitations apply to the overall study:
Pain will differ from individual to individual prior to and after root canal
therapy.
Age differences will exist among the patients.
Gender differences will exist among the patients.
Health histories will differ among the patients.
Different teeth in the arch will be used.
Etodolac may affect patients differently.
Patient must return the pain survey in order for the data to be collected.
Endodontic diagnosis is not an exact science.
Some patients may be taking antibiotics for the involved tooth.
DELIMITATIONS
The following delimitations may apply to the overall study:
Diagnosis of each tooth will be determined and recorded.  A particular
pulpal or periapical diagnosis is not required to be considered for the
study.
The patient must be 18 years or older.
A history of one of the following conditions will contraindicate the use of
the patient for the study; mitral valve prolapse, rheumatic heart
disease, artificial heart valves or joints, myocardial infarction, stroke,
6untreated hypertension, hyperthyroidism, hepatitis, epilepsy, bleeding
disorders, stomach ulcers, kidney problems, liver problems, currently
pregnant, or current use of medications contraindicated with NSAIDs.
A patient will not be considered for evaluation if he/she has taken any type
of pain medication within 6 hours of the scheduled root canal therapy.
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REVIEW OF LITERATURE
Root canal therapy is regarded by the public as being a painful experience. 
Surveys conducted by the American Association of Endodontists reveal that over half of
the patients referred to endodontists are in pain (15).  Most patients that endodontists treat
are in pain prior to root canal therapy.  Once treatment has been rendered, pain can still
persist. 
Certain preoperative clinical factors and some iatrogenic circumstances during
treatment can predispose individuals to post-endodontic pain.  Seltzer, Bender, and
Ehrenreich treated 653 patients with a variety of intracanal medicaments during multivisit
root canal therapy.  40% of the patients experienced pain after treatment.  The incidence
of pain was found to be significantly greater in patients with acute pulpitis or acute
pericementitis (periodontitis) than patients with chronic pulpitis or chronic pericementitis
(periodontitis).  The stage of instrumentation (complete or incomplete) was not related to
incidence or duration of pain.  No difference was found in the incidence or severity of
pain regardless of which pair of drugs were compared.  Patients older than 21 years
8experienced more postoperative pain than younger patients (16).
O’Keefe concluded in 1976, that a significant relationship existed between
preoperative, operative, and postoperative endodontic pain levels.  Patients with severe
postoperative pain tended to have more severe operative and postoperative pain than
patients with mild or no preoperative pain.  He also found posterior teeth were more
likely to cause postoperative pain and patients older than 20 years of age experienced
postoperative pain significantly more often than younger patients (2).
In 1970 Fox et., al., examined 291 one-visit root canal therapy procedures.  They
reported that tooth vitality did not have a significant effect on postoperative pain. 
However, they did conclude that teeth without radiolucent apical areas were associated
with more postoperative pain than those with an apical radiolucency.  They also found
that females were more susceptible to postoperative pain than males (17).
Genet, et., al., evaluated preoperative and operative factors and their association
with the incidence of postoperative pain after the first session of root canal treatment.  A
positive correlation occurred with postoperative pain and the following factors: 1) the
presence of preoperative pain in conjunction with a non-vital pulp; 2) the presence of a
radiolucency larger than 5 mm in diameter; 3) the number of canals in the treated tooth;
and 4) women reported more postoperative pain than men (18).
Harrison, Baumgartner, and Svec published two reports dealing with the incidence
of pain associated with endodontic treatment.  The first study found that the degree of
pain remained constant regardless of whether the teeth were; vital or non-vital; previously
opened or intact; single rooted or multirooted;  anterior or posterior; maxillary or
9mandibular.  The second paper reported the following; 1) postfilling pain would most
likely occur within 24 hours after filling, or not at all; 2) pain was not associated with the
preoperative condition; 3) if patients had pain during treatment there was an increased
likelihood of postfilling pain; and 4) less pain occurred in patients who were irrigated
with 3% hydrogen peroxide and 5.25% sodium hypochlorite and medicated with
formocresol (19,20).
In summary, some studies found that certain preoperative characteristics lead to
postoperative pain, while others found that those same characteristics have no effect on
postoperative pain.  Genet found that a radiolucency of 5 mm or greater produced
postoperative pain in multivisit root canal therapy, while Fox found that a radiolucency
was less likely to cause postoperative pain in one visit root canal therapy.  Preoperative
conditions may assist the practitioner in determining if the patient will experience
postoperative pain but other factors can also produce post-endodontic pain.
 Certain iatrogenic circumstances can lead to post-endodontic pain.  The operator
can induce post-endodontic pain by extruding debris, instruments, paper points, filling
materials, or disinfectant outside of the canal and into the periapical tissues (21). 
Unfortunately these situations are sometimes unavoidable and result in post-endodontic
pain.   
The number of office visits required to complete root canal therapy has been
continually argued.  The incidence of postoperative pain between one-visit endodontics
and multiple-visit endodontics has been explored.  Fox, et., al., evaluated postoperative
pain in 247 teeth following complete, one-visit endodontic treatment.  Within 24 hours
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following treatment, 90% of the patients showed little or no spontaneous pain and 82%
had little or no percussion sensitivity (17).  Morse, et., al., studied 200 cases and found
98.5% of the patients showed no or slight pain after one appointment root canal therapy
(22).    In 1982, Mulhern et., al., concluded that no difference existed in postoperative
pain and the number of visits required to complete the root canal procedure (23).  From
these conclusions, the root canal therapy procedures completed in this study were
performed in one visit, if time allowed.  
Ideally, root canal therapy would eliminate all pain that exists in the involved
tooth.  Unfortunately, the physiodynamics of the inflammatory process do not allow for
pain to immediately disappear once the source of the pain is removed.  An acute
inflammatory process causes increased hydrodynamic pressure in the periodontal
ligament space, resulting in a pain response.  This inflammatory process may arise from
procedures completed during the root canal procedure.  These include; hemorrhage
resulting from pulpal extirpation, cleaning and shaping of the root canal systems,
irrigation, intracanal medications, and/or root canal obturating materials (24).  
Injury to the periradicular tissue initiates the inflammatory cascade.  Inflammatory
mediators; histamine, serotonin, bradykinin, prostaglandin, and leukotriene are released,
causing increased vascular permeability and eventually pain (3,4).
Evaluation of analgesic agents to control acute dental pain has been achieved with
the use of oral surgery models that involve removal of third molars.  Gaston, Mallow, and
Frank evaluated the analgesic efficacy of etodolac for 161 patients reporting moderate to
severe pain after an oral surgery procedure (surgical removal of multiple teeth or
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extensive multiple extractions with alveoplasty).  The patients were given single oral
doses of one of the following test drugs: aspirin 650 mg; etodolac 50 mg; etodolac 200
mg; or a placebo.  All active drugs were found to be significantly more effective than a
placebo.  The 200 mg dose of etodolac provided an earlier onset and longer duration of
analgesia than the other test drugs (11).  
Fliedner, Levsky, and Kechejian evaluated 380 adult outpatients experiencing
postoperative pain following the extraction of one or more third molars.  Three studies
were conducted with these patients.  In two of the studies, four treatment groups were
compared: etodolac (100 mg and 200 mg); aspirin (650 mg); and a placebo.  In the third
study, three dose levels of etodolac (50 mg, 100 mg, and 200 mg) were compared with
aspirin (650 mg), and a placebo.  Etodolac dosages of 100 mg and 200 mg were found to
be comparable or superior in analgesic efficacy to 650 mg of aspirin and had a longer
duration in all three studies (12).
Winter, et., al., compared the effectiveness of 400 mg and 800 mg of ibuprofen to
650 mg of aspirin, 65 mg of propoxyphene HCl, and a placebo in 510 patients
experiencing pain subsequent to oral surgery procedures.  Ibuprofen, at both doses, was
shown to be more effective for both degree and duration of relief from pain (25).  
These studies evaluated the efficacy of pain medications given after treatment was
rendered.  Other studies have been done to evaluate the effectiveness of preoperative
administration of analgesics on post-surgical pain.
In 1978, Dionne and Cooper evaluated the analgesic effects of preoperatively
administering 400 mg of ibuprofen on postoperative pain after the surgical removal of
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impacted third molars on 100 patients.  They concluded that pretreatment of ibuprofen
delayed the mean time of onset of postoperative pain more than 100 minutes, as
compared to pretreatment with a placebo.  The severity of pain initially experienced
postoperatively was less in the group treated preoperatively with ibuprofen (26).  
Dionne et., al., continued to study preoperative administration of ibuprofen for
removal of impacted third molars in 1983.  Subjects were given 800 mg ibuprofen prior
to the procedure and 400 mg ibuprofen 4 and 8 hours later.  Comparison was made to
groups receiving either placebo at all three doses, 600 mg acetaminophen administered on
the same schedule, or preoperatively administered placebo followed by two doses of
postoperatively administered 600 mg acetaminophen plus 60 mg codeine.  Ibuprofen
pretreatment resulted in significantly less pain than placebo or acetaminophen
pretreatment as the local anesthetic wore off.  Ibuprofen also resulted in less
postoperative pain than acetaminophen plus codeine following the second dose.  The
results of these studies suggest that it is possible to delay the onset and lessen the severity
of postoperative pain by preoperative administration of a nonsteroidal anti-inflammatory
drug, such as ibuprofen (7).
These studies evaluated oral surgery models, while other studies have been
completed to evaluate the efficacy of pre-operative medication and their effect on post-
endodontic pain.  Flath concluded that prophylactic administration of flurbiprofen
significantly reduced post-endodontic pain in patients who were symptomatic before
treatment, compared to patients who received a placebo (27). 
Torabinejad et., al., evaluated the effectiveness of nine different medications on
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postoperative pain following complete instrumentation and following root canal
obturation.  In the first study, three factors (preoperative pain, apprehension, and types of
medication) were found to be significant in determining postinstrumentation pain.  As the
intensity of preoperative pain increased, the chances for more severe postoperative pain
increased.  An association between the presence of apprehension before any treatment and
postoperative pain was also noted.  Patients with mild to moderate pain showed no
significant difference between the effectiveness of different medications and a placebo in
combating postoperative pain.  In patients with moderate to severe preoperative pain,
ibuprofen, ketoprofen, erythromycin base, penicillin, and methylprednisolone plus
penicillin were more effective in controlling postoperative pain than a placebo within the
first 48 hours following complete instrumentation (28).  In the second study, the
incidence of postoperative pain after obturation was lower than that of cleaning and
shaping (5.83% versus 21.76%).  In addition, no difference was found between the
effectiveness of the various medications and a placebo in controlling postoperative pain
following obturation (29).
Evaluation of pain and pain relief has been studied using several methods. 
Seymour studied the use of pain scales in assessing the efficacy of analgesics in
postoperative dental pain and found that a 10 cm visual analog scale was more sensitive
than other pain scales and could discriminate between small changes in pain intensity
(30).   Scoot and Huskisson determined that visual analog and graphic rating scales are
the best available method for measuring pain or pain relief (31).    
 The ultimate goal of analgesic use is pain relief.  Nonsteroidal anti-inflammatory
14
drugs inhibit prostaglandin synthesis by decreasing the activity of the enzyme cyclo-
oxygenase, which results in decreased formation of prostaglandin precursors. 
Researchers have discovered that the cyclo-oxygenase enzyme exists as two separate
entities, Cox-1 and Cox-2.  Cox-1 synthesizes protective prostaglandins, which preserve
the integrity of the stomach lining and maintain normal renal function.  Cox-2 is induced
by pro-inflammatory cytokines and growth factors, which implies that Cox-2 plays a role
in both inflammation and control of cell growth (6).  Etodolac, a nonsteroidal anti-
inflammatory agent, has proven to have a high affinity for the Cox-2 enzyme (13,14).
Etodolac has also been proven to be an effective analgesic for rheumatoid arthritis, and in
post oral surgery models, but its ability to decrease post-endodontic pain by prophylactic
administration has not been investigated (9-12).  
15
CHAPTER III
MATERIALS AND METHODS
SAMPLE DESCRIPTION
This study involved forty-two patients who required conventional root canal
therapy.  Each patient was registered and treated at the West Virginia University Dental
Clinic and was eighteen years of age or older.  A medical history was taken for each
patient.  A history of one of the following conditions contraindicated the use of the
patient for the study; mitral valve prolapse, rheumatic heart disease, artificial heart valves
or joints, myocardial infarction, stroke, untreated hypertension, hyperthyroidism,
hepatitis, epilepsy, bleeding disorders, stomach ulcers, kidney problems, liver problems,
currently pregnant, or current use of medications contraindicated with NSAIDs.    Patients
were only treated by endodontic residents.  The patients were required to pay the West
Virginia University Dental School’s Resident Fee for the root canal procedure (molar =
$350.00; premolar = $300.00; anterior = $200.00).  The patients were not charged for the
medication and were reimbursed $5.00 for completing and returning the pain survey.
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RESEARCH DESIGN
This study assessed the ability of prophylactic oral administration of etodolac to
reduce post-endodontic pain when compared to ibuprofen, and a placebo.  Visual analog
scales were used to collect the data over time.  The data was analyzed to determine if any
difference existed between etodolac, ibuprofen, and a placebo and their ability to reduce
post-endodontic pain.  
CLINICAL EXAM.  Informed consent was obtained and a clinical exam
(Appendix C) was administered.  The exam included; cold testing (with Endo-Ice),
percussion and palpation evaluation, periodontal probing, mobility assessment, and a
periapical radiograph.  All past and present symptoms of the involved tooth were
recorded.  A pulpal and periapical diagnosis was determined from the data collected in
the exam and was recorded.  Data collected in the clinical exam was applied to the flow
charts in Appendix E to determine the pulpal and periapical diagnosis.
VISUAL ANALOG SCALE.  Prior to administration of the medication, each
patient recorded his/her initial perception of pain on the pain survey (Appendix D).  Pain
intensity was measured using a 100 mm visual analog scale (VAS).  The scale was from
zero to one-hundred, zero being “no pain” and one-hundred being “pain so severe you
can’t stand it”.  The pain survey included a VAS for; immediately after root canal
therapy, 4 hours after, 8 hours after, 12 hours after, 24 hours after, 48 hours after, and 72
hours after root canal therapy was initiated.  The pain survey also included an area to
17
indicate if additional medication was required after each corresponding time interval.
METHODOLOGY
Forty-two patients were recruited for this study.  All medications are reported to
be safe and effective for pain and inflammation by their manufactures.  Upon approval by
the Institutional Review Board of West Virginia University, (Appendix A), a consent
form (Appendix B) was signed by all patients prior to treatment.  Patients consented to
single blinded oral administration of either 400 mg of etodolac, 600 mg of ibuprofen, or a
placebo (Cebocap 3 - Orange), prior to conventional root canal therapy.   The three test
medications were randomized using a spreadsheet program (Microsoft Excel) into a
group of twenty-one. (Appendix F)  The randomization sequence was repeated after the
first twenty-one participants were evaluated.  After oral administration of the test
medication, the patient filled out his/her initial perception of pain on the pain survey. 
Local anesthetic was administered and endodontic access was achieved under rubber dam
isolation.  Cleaning and shaping of the canal systems was achieved in the following
manner; early negotiation and cleaning and shaping was completed with Flex-O-Files #8,
#10, #15, #20, #25.  An initial working length radiograph was taken.  The working length
was estimated to be 1 mm short of the radiographic apex.  Gates Glidden Burs #2, #3, and
#4 were used to enlarge the coronal aspect of the canals.  Taper of each canal was
achieved with Profile GT rotary files.  Profile ISO 0.04 taper files and/or Flex-O-Files
were used to create an apical stop at the working length of each canal.  Final working
18
lengths were confirmed with a radiograph.  Irrigation was completed with 5.25% sodium
hypochlorite.  RC Prep was used with the Profile GT and the ISO 0.04 rotary files for
lubrication.
Cold lateral condensation was used to complete the obturation of each canal.  
Dia-Dent 0.04 taper gutta percha cones were customized to fit each canal with a gutta
percha gauge.  The gutta percha cones were measured and introduced into the canal to
reconfirm the correct working length.  Grossman’s sealer was placed into each canal with
the master apical file.  The master gutta percha cone was dipped in sealer and placed into
the canal.  Accessory gutta percha points were placed after the use of a D-11 endodontic
spreader.  Each canal received enough accessory gutta percha points to create a dense
three dimensional fill.  Thirty-seven of the forty-two cases were completed in one
appointment (access, cleaning/shaping and obturation).
A cotton pellet was placed in the pulp chamber space and cavit was used as a
temporary filling material.  The occlusion was evaluated and reduced when necessary. 
Final radiographs were taken and the patient was instructed to return to his/her general
dentist for a final restoration.  
The patient immediately recorded his/her pain perception on the pain survey after
completion of the appointment.  He/she also recorded his/her pain perception at 4, 8, 12,
24, 48, and 72 hours after root canal therapy was initiated.  Postoperative instructions and
an extra dosage of the test medication was given to the patient.  The patient was
instructed to take the extra medication only if needed and record the time it was taken on
the pain survey.
19
DATA COLLECTION
The VAS’s were measured with a standard millimeter ruler and recorded in the
data collection sheet (Table 1).  Additional data, was also recorded on the data collection
sheet.  This included: test medication taken (Med #), gender, if the patient was taking any
medications for conditions other than the involved tooth (Meds), if antibiotics were being
taken for the tooth (Anti), pulpal diagnosis (Pulp Dx), periapical diagnosis (Peri Dx), if
the canals were obturated (Obtur), if there was an existing restoration (Rest), if additional
medication was required after root canal therapy because of post-endodontic pain (X-
Meds).  Table 2 consists of a legend for the data collection sheet.  
STATISTICAL ANALYSIS
Two sets of data were analyzed.  The first set compared each medication and the
corresponding VAS values for each patient at each time variable.  The second set
compared the need for extra medication after the completion of root canal therapy with
the following: periapical diagnosis, pulpal diagnosis, and if antibiotics were being taken
for the tooth,.  The first set of data was analyzed using a two-way ANOVA Test.
(P<0.05).  The second set of data was analyzed using a Chi-Square Test (P<0.05).
EQUIPMENT AND MATERIALS
The following is a list of materials and equipment used in the study:
Etodolac (Lodine) - 200 mg capsules (Ayerst Labs, Philadelphia, PA)
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Ibuprofen (Advil) - 200 mg gel caplets (Whitehall-Robins, Madison, NJ)
Placebo (Cebocap 3) - orange capsules (Forest Pharm., St. Louis, MO)
White Gelatin Capsules - Size 1 (Frontier, Norway, IA)
42 individuals requiring conventional root canal therapy
Local Anesthetic (Astra, Westborough, MA)
Flex-O-Files (Dentsply, Milford, DE)
ProFile GT and ISO 0.04 Taper Rotary Files (Tulsa Dental, Tulsa, OK)
Gates-Glidden Burs (Dentsply, Milford, DE)
Standard School of Dentistry Endodontic Set-Up, including Rubber Dam
Cavit (ESPE, Germany)
Roth Root Canal Cement - Type 801 Elite Grade (Roth Inter., Chicago,IL)
5.25% Sodium Hypochlorite (The Clorox Company, Oakland, CA)
RC Prep (Premier, Norristown, PA)
Endodontic Paper Points (Dentsply, Milford, DE) 
Endo-Ice (Hygenic, Akron, OH)
Ektaspeed Plus Dental Film - Size 2 (Kodak, Rochester, NY)
DiaPro 0.04 Taper Gutta Percha Points (DiaDent, Burnaby, B.C., Canada) 
Gutta Percha Gauge (Dentsply, Milford, DE)
Accessory Gutta Percha Points (Dentsply, Milford, DE)
Standard Millimeter Ruler
Medical History Form
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CHAPTER IV
RESULTS AND DISCUSSION
RESULTS
Table 1 is a collection of all the data.  Forty-two subjects were entered into the
study.  One subject did not return his pain survey, and five subjects did not have their
tooth obturated; therefore, they were dropped from the study and only thirty-six subjects
were analyzed.  (Subject numbers seventeen, eighteen, twenty-three, twenty-nine, thirty,
and thirty-two were not analyzed).  Twelve subjects received etodolac, twelve received
ibuprofen, and twelve received a placebo prior to root canal therapy.   The subjects
recorded their perceived pain on a VAS.  The values from each VAS were recorded at
each time interval.  (Initial, Immediately After, 4 Hrs, 8 Hrs, 12 Hrs, 24 Hrs, 48 Hrs, and
72 Hrs after initiation of root canal therapy).  Zero equaled, “no pain”, and one hundred
equaled, “pain so severe you can’t stand it”.  Twenty-two females and fourteen males
participated in the study.  Nineteen of the thirty-six subjects were taking some type of
daily medication that was not for tooth pain.  Six of the thirty-six subjects were taking
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antibiotics for their tooth.  The antibiotics included Penicillin VK, (three subjects);
cephalexin, (two subjects); and clindamycin, (one subject).  The pulpal and periapical
diagnosis was determined using the diagnosis flow charts and were recorded.  Nine
patients presented with a normal pulp, eleven presented with an irreversible pulpitis, and
sixteen presented with a necrotic pulp.  Nine patients presented with a normal periapex,
twelve presented with an Acute Apical Periodontitis (AAP), eight presented with a
Chronic Apical Periodontitis (CAP), one presented with a Chronic Apical Abscess
(CAA), and six presented with a Phoenix Abscess.  Twenty-nine of the thirty-six subjects
presented with an existing restoration on the involved tooth.  Eleven subjects required
additional medication to relieve post-endodontic pain.
Figure 1 shows the comparison of each medication and its ability to reduce pain at
each time interval.  When comparing the ability of ibuprofen to both etodolac and a
placebo after four and eight hours from initiation of root canal therapy, ibuprofen is
significantly more effective at reducing pain (4 Hours P-value = 0.0111;
8 Hours P-value = 0.0397).  Table 3 includes the means and standard deviations for each
medication at each time interval.
Table 4 and Figure 2 display the number of subjects who presented with each
periapical diagnosis.  They also show the number of subjects who required additional
medication for post-endodontic pain and their corresponding periapical diagnosis.  Nine
subjects presented with a normal periapex and zero required additional medication for
post-endodontic pain.  Twelve subjects presented with AAP and six required additional
medication for post-endodontic pain.  Eight subjects presented with CAP and one
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required additional medication for post-endodontic pain.  One subject presented with
CAA and did not require additional medication for post-endodontic pain.  Six subjects
presented with a Phoenix Abscess and four required additional medication for post-
endodontic pain.  A Chi-square analysis showed that a significant difference existed for
the periapical diagnosis and the need for additional medication.  (P-value = 0.0077). 
Patients who presented with a periapical diagnosis of an Acute Apical Periodontitis or a
Phoenix Abscess were more likely to require additional medication for post-endodontic
pain than patients who presented with a periapical diagnosis of a Normal Periapex, a
Chronic Apical Periodontitis, or a Chronic Apical Abscess.
Table 5 and Figure 3 display the number of subjects who presented with each
pulpal diagnosis.  They also show the number of subjects who required additional
medication for post-endodontic pain and their corresponding pulpal diagnosis.  Nine
subjects presented with a normal pulp and two subjects required additional medication for
post-endodontic pain.  Eleven subjects presented with an irreversible pulpitis and three
subjects required additional medication for post-endodontic pain.  Sixteen subjects
presented with a necrotic pulp and six required additional medication for post-endodontic
pain.  A Chi-square analysis showed that no significant difference existed for the pulpal
diagnosis and the need for additional medication.  (P-value = 0.7524).
Table 6 and Figure 4 displays that six subjects were taking antibiotics prior to root
canal therapy.  Three subjects were taking Penicillin VK, two subjects took cephalexin,
and one subject took clindamycin.  The amount and duration of use of each antibiotic was
unknown for each patient.  Of the six subjects taking antibiotics prior to root canal
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therapy, four required additional medication for post-endodontic pain.  Thirty subjects
were not taking antibiotics prior to root canal therapy, and only seven required additional
medication for post-endodontic pain.  A Chi-square analysis did not find a significant
difference for the use of antibiotics prior to root canal therapy and the need for additional
medication, but it was close.  (P-value = 0.0517).  The six subjects who were taking
antibiotics prior to root canal therapy had the following periapical diagnoses: AAP = 2,
CAP = 1, and Phoenix Abscess = 3.  The four subjects who required additional
medication had a periapical diagnosis of the following: AAP = 1, CAP = 1, Phoenix
Abscess = 2.          
Gender did not play a role in the need for additional medication.
Table 1.
Data Collection Sheet
Sub # Med # Initial Imm After 4 Hrs 8 Hrs 12 Hrs 24 Hrs 48 Hrs 72 Hrs Gender Meds Anti Pulp Dx Peri Dx Obtur Rest X-Meds
1 0 0 0 11 9 3 1 0 0 1 0 0 1 0 1 1 0
2 2 5 1 1 4 8 9 0 2 1 1 1 2 5 1 1 0
3 1 0 0 5 0 0 0 0 0 0 0 0 0 0 1 0 0
4 2 0 7 28 31 31 23 22 22 1 1 0 0 0 1 1 0
5 0 4 2 13 13 49 4 6 8 1 1 0 0 1 1 1 1
6 1 70 0 0 27 61 13 0 0 1 0 0 1 1 1 1 1
7 2 0 1 3 1 1 1 0 0 0 0 0 2 2 1 1 0
8 0 46 1 56 45 42 7 4 0 1 1 1 2 5 1 1 1
9 1 2 0 0 0 0 1 6 0 1 0 0 1 2 1 1 0
10 0 14 0 0 0 0 0 0 0 0 1 1 2 1 1 1 0
11 1 0 0 0 4 3 1 0 0 0 0 0 0 0 1 1 0
12 0 4 14 3 3 0 0 0 0 1 0 0 2 2 1 0 0
13 0 1 0 1 1 96 22 20 2 0 1 0 0 1 1 0 1
14 2 0 5 14 47 58 89 96 99 1 0 0 2 5 1 1 1
15 2 63 32 22 24 3 4 2 1 0 1 1 2 5 1 1 1
16 2 0 0 0 0 0 0 0 0 1 1 0 0 0 1 1 0
17 0 0 0 76 0 0 0 0 0 1 0 0 0 0 0 0 1
18 2 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0
19 1 0 0 0 0 0 0 0 0 0 1 0 2 2 1 1 0
20 1 99 0 26 17 66 43 28 16 1 1 0 1 1 1 0 1
21 1 13 23 9 5 3 50 39 13 1 1 0 1 1 1 1 1
22 0 0 0 0 0 9 10 0 0 1 0 0 0 0 1 1 0
23 2 1 2 84 0 0 0 0 0 0 0 0 1 1 0 1 1
24 1 0 0 0 0 0 2 3 0 1 1 1 2 2 1 0 1
25 2 0 0 0 0 4 0 0 0 1 0 0 2 2 1 1 0
26 0 15 11 34 26 2 0 0 0 0 0 0 1 1 1 1 0
27 1 0 0 0 21 30 8 0 0 1 0 0 2 2 1 1 0
28 2 3 4 3 3 4 0 0 0 1 1 0 1 1 1 1 0
29 0 0
30 1 3 0 9 6 3 3 1 0 1 0 0 1 0 0 1 0
31 0 0 0 6 6 7 9 0 0 1 1 1 2 1 1 1 1
32 1 2 2 6 2 1 0 0 0 0 0 0 2 2 0 1 0
33 0 3 4 2 2 2 2 3 3 1 0 0 1 1 1 1 0
34 0 85 10 29 32 17 5 5 5 0 0 0 2 5 1 0 1
35 2 0 0 0 0 0 0 0 0 1 0 0 2 5 1 1 0
36 2 0 0 0 0 0 0 0 0 1 1 0 1 0 1 1 0
37 2 37 0 0 0 0 0 0 0 0 0 0 1 0 1 1 0
38 0 0 0 5 6 2 1 1 1 0 0 0 0 0 1 1 0
39 2 4 0 6 5 2 0 0 0 0 1 0 1 1 1 1 0
40 1 10 1 0 1 1 1 0 0 0 1 0 2 4 1 1 0
41 1 5 0 3 4 4 3 1 2 0 1 0 0 1 1 0 0
42 1 0 0 0 0 0 0 0 0 1 1 0 2 2 1 1 0
Table 2.
Data Collection Sheet Legend
Med # 0 = Placebo 1 = Ibuprofen 2 = Etodolac
Gender 0 = Male 1 = Female
Meds 0 = No 1 = Yes
Anti 0 = No 1 = Yes
Pulp Dx 0 = Normal 1 = Irreversible Pulpitis 2 = Necrotic Pulp
Peri Dx 0 = Normal 1 = AAP 2 = CAP 3 = AAA 4 = CAA 5 = Phoenix Abscess
Obtur 0 = No 1 = Yes
Rest 0 = No 1 = Yes
X-Meds 0 = No 1 = Yes
All subjects and corresponding data that are shaded gray in Table 1 were not analyzed
  = significant difference exists for P<0.04
Figure 1.
Experimental Medications and Pain Relief Over Time
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Table 3.
Means and Standard Deviations
Medication Time Mean Standard Deviation
Placebo Immediately After RCT -10.83 24.42
Placebo 4 Hours After RCT -1 19.18
Placebo 8 Hours After RCT -2.42 17.3
Placebo 12 Hours After RCT 4.75 38.07
Placebo 24 Hours After RCT -9.25 26.89
Placebo 48 Hours After RCT -11.08 26.1
Placebo 72 Hours After RCT -12.75 25.26
Ibuprofen Immediately After RCT -14.58 33.52
Ibuprofen 4 Hours After RCT -13 27.55
Ibuprofen 8 Hours After RCT -10 26.93
Ibuprofen 12 Hours After RCT -2.58 14.1
Ibuprofen 24 Hours After RCT -6.42 25.96
Ibuprofen 48 Hours After RCT -10.17 29.42
Ibuprofen 72 Hours After RCT -14 29.46
Etodolac Immediately After RCT -5.17 13.87
Etodolac 4 Hours After RCT -2.92 18.97
Etodolac 8 Hours After RCT 0.25 23.48
Etodolac 12 Hours After RCT -0.08 29.12
Etodolac 24 Hours After RCT 1.17 34.81
Etodolac 48 Hours After RCT 0.67 36.72
Etodolac 72 Hours After RCT 1 37.56
* The mean equals the change in pain from the initial perception of pain.
Table 4.
Periapical Diagnosis and Additional Medication
Periapical Dx Subjects Subjects Requiring Extra Meds
Normal 9 0
AAP 12 6
CAP 8 1
CAA 1 0
Phoenix Abscess 6 4
Figure 2.
Periapical Diagnosis and Additional Medication
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Table 5.
Pulpal Diagnosis and Additional Medication
Pulpal Dx Subjects Subjects Requiring Extra Meds
Normal 9 2
Irreversible Pulpitis 11 3
Necrotic Pulp 16 6
Figure 3.
Pulpal Diagnosis and Additional Medication
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Table 6.
Antibiotics Taken for Tooth and Additional Medication
Antibiotics Taken for Tooth Subjects Subjects Requiring Extra Meds
Yes 6 4
No 30 7
Figure 4.
Antibiotics Taken for Tooth and Additional Medication
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DISCUSSION
Prophylactic oral administration of a non-steroidal anti-inflammatory drug has
been proven to reduce postoperative pain in oral surgery models and in root canal therapy
models (7,8,11,12,25,26).  By administering NSAIDs prior to root canal therapy, the
cyclo-oxygenase pathway can be blocked and the pain sensation can be prevented before
it even begins.  Ibuprofen was significantly better at reducing pain after four and eight
hours from initiation of root canal therapy compared to etodolac and a placebo.
From the diagnosis flow charts a Phoenix Abscess and an Acute Apical
Periodontitis both have the characteristic of pain to percussion.  As stated by O’Keefe, a
significant relationship exists between preoperative and postoperative endodontic pain. 
Patients with severe preoperative pain tend to have more severe operative and
postoperative pain than patients with mild or no preoperative pain (2).  Torabinejad found
as the intensity of preoperative pain increased, the chances for more severe postoperative
pain increased (28,29).  Eighteen patients presented with pain to percussion and ten of
them required additional medication to reduce post-endodontic pain.  This study indicated
that if a patient originally presents with pain to percussion, it is likely that he/she will
need additional medication to relieve post-endodontic pain.  
The characteristics of a Chronic Apical Periodontitis include a radiolucency at the
root apex and no pain to percussion.  A Chronic Apical Abscess consists of a
radiolucency at the root apex, a draining fistula (sinus tract), and usually no pain to
percussion.  A patient presenting with a periapical diagnosis of a CAP, CAA, or a normal
periapex is not experiencing pain before root canal therapy; therefore, he/she is less likely
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to experience post-endodontic pain.  In this study, eighteen patients presented with a
normal periapex, CAP, or CAA, and only one required additional medication for post-
endodontic pain. 
This study found that a significant difference did not exist for the pulpal diagnosis
and the need for additional medication after completion of root canal therapy.  It can be
argued that after the pulp (the source of the infection) is removed, the inflammatory
cascade is halted and additional medication may not be required for postoperative pain. 
Six patients were taking antibiotics for their tooth prior to root canal therapy. 
Four of those six required additional medication for post-endodontic pain.  Antibiotics
function to provide time for the normal host defenses to gain control and eventually
eliminate the infectious process.  A patient taking antibiotics usually presents with
swelling and/or pain.  If the patient presents for root canal therapy in pain, he/she is more
likely to experience post-endodontic pain.  In this study six patients presented for root
canal therapy taking antibiotics and four required additional medication for post-
endodontic pain.
Periapical diagnoses of an AAP and a Phoenix Abscess both are painful to
percussion.  After performing root canal therapy on a tooth that is painful to percussion, it
seems logical to reduce the occlusion.  A recent study by Rosenberg, et., al., found that
occlusal reduction should prevent postoperative pain in those patients whose teeth
initially exhibit pulp vitality, percussion sensitivity, preoperative pain, and/or the absence
of a periradicular radiolucency (32).  From Rosenberg’s study and this study’s findings,
perhaps all teeth presenting with a periapical diagnosis of an AAP or a Phoenix Abscess
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should have the occlusion completely reduced after root canal therapy.    
In 1991, researchers discovered that the cyclo-oxygenase enzyme exists as two
separate entities; Cox-1 and Cox-2.  Cox-1 synthesizes protective protaglandins, which
preserve the integrity of the stomach lining.  Cox-2 is mostly responsible for producing
prostaglandins for pain and inflammation (6).  
Etodolac has been proven to have a high affinity to block the Cox-2 enzyme
(13,14).  It seems logical to administer a drug that will selectively block prostaglandins
that produce pain and inflammation, while not interrupting production of prostaglandins
that protect the stomach lining.  This study found that administering 600 mg of ibuprofen
prior to root canal therapy was more effective at reducing post-endodontic pain at four
and eight hours after initiation of treatment, when compared to 400 mg of etodolac and a
placebo.  
Ibuprofen blocks both the Cox-1 and Cox-2 enzymes but it is a safe, inexpensive,
and effective analgesic and anti-inflammatory for post-endodontic pain.  Etodolac blocks
the Cox-2 enzyme but was not as effective for post-endodontic pain as ibuprofen. 
Perhaps etodolac does not have a high affinity for the inflammatory components of an
endodontic infection or perhaps there is an unknown inflammatory component that
ibuprofen has a high affinity for that etodolac will not block.  
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CHAPTER V
SUMMARY AND CONCLUSIONS
SUMMARY
Root canal therapy induces post-endodontic pain (2,16-24).  The purpose of this
study was to determine if prophylactic oral administration of etodolac would significantly
decrease post-endodontic pain when compared to ibuprofen, and when compared to a
placebo.  
It was hypothesized that etodolac would provide significantly better pain relief
when compared to ibuprofen and a placebo.  It was also hypothesized that the pulpal or
periapical diagnosis of the tooth would not affect the ability of the medication to decrease
post-endodontic pain.
Forty-two subjects were given oral prophylactic administration of either 400 mg
of etodolac, 600 mg of ibuprofen, or a placebo prior to root canal therapy.  One subject
did not return his pain survey.  Five subjects did not have their root canals obturated;
therefore, thirty-six subjects were analyzed. (Twelve for each medication)
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A significant difference was found for the ability of ibuprofen to reduce post-
endodontic pain after four and eight hours after initiation treatment, when compared to
etodolac and a placebo.  A significant difference was also found for the periapical
diagnosis and the need for additional medication after root canal therapy was completed. 
A periapical diagnosis of an Acute Apical Periodontitis or a Phoenix Abscess,
significantly required the need for additional medication compared to a periapical
diagnosis of a Normal Periapex, Chronic Apical Periodontitis, or a Chronic Apical
Abscess.  A significant difference did not exist for the pulpal diagnosis and the need for
additional medication.  A significant difference did not exist if the patient was taking
antibiotics for the involved tooth and the need for additional medication for post-
endodontic pain.
This study found when performing conventional root canal therapy, if the patient
presents with a periapical diagnosis of an Acute Apical Periodontitis or a Phoenix
Abscess he/she is more likely to require additional pain medications to relieve post-
endodontic pain compared to a periapical diagnosis of a Normal Periapex, a Chronic
Apical Periodontitis, or a Chronic Apical Abscess.  Rosenberg found that occlusal
reduction should prevent postoperative pain in patients who exhibit pulp vitality,
percussion sensitivity, preoperative pain, and/or absence of a radiolucency (32).   From
Rosenberg’s study and this study’s findings, perhaps all teeth presenting with a periapical
diagnosis of an AAP or a Phoenix Abscess should have the occlusion completely reduced
after root canal therapy to eliminate post-endodontic pain.
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CONCLUSIONS
Two conclusions can be drawn from this study:
1.  Prophylactic ibuprofen will significantly reduce post-endodontic pain at four       
     and eight hours after initiation of treatment, when compared to etodolac and a     
     placebo.
2.  A patient presenting for root canal therapy, with a periapical diagnosis of an        
     Acute Apical Periodontitis or a Phoenix Abscess, is more likely to require           
     additional medication to relieve post-endodontic pain compared to a periapical   
     diagnosis of a Normal Periapex, a Chronic Apical Periodontitis, or a Chronic      
     Apical Abscess. 
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            APPENDIX A
Institutional Review Board Approval Form
DATE:
The Institutional Review Board for the Protection of Human Subjects
West Virginia University- .__.__  _.___.___  ._ _.._ __.____  ____  ___  ____-
NOTICE OF APPROVAL FOR PROTOCOL H.S. #14146 Addm. #2
(Changing back to original drug and title)
This research will be monitored for re-approval annually.
This protocol was first approved on May 14, 1998.
TO: Eric Menke
Project Title : The Effectiveness of Prophylactic Etodolac on Post
Endodontic  Pain
SPONSORING AGENCY: N/A
The Institutional Review Board for the Protection of Human
Research Subjects (IRB)  has approved the project described above.
Approval was based on the descriptive material and procedures you
submitted for review . Should any changes in your protocol/consent
form be necessary, prior approval must be obtained from the IRB.
According to the Code of Federal Regulations, Section
312.32, investigators are required to notify the FDA and the
study sponsor of any adverse experience associated with the use
of an investigational drug that is serious and unexpected. A
serious adverse experience is considered any event that is fatal
or life-threatening,  is permanently disabling, requires inpatient
hospitalization,  or is a congenital anomaly, cancer, or overdose.
An unexpected adverse experience is an event that is not
identified in nature, severity , or frequency in the current
investigator brochure.  Any experience reportable to FDA and the
sponsor must also be reported immediately to the IRB.
A consent form* X is  is not required of each subject.- -
An assent form  is X  is not required of each subject.- -
A recruitment ad has  has not X been approved.
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304 293-7073 q FAX 304 293-7435 q 666 Chestnut Ridge, Room 202 q PO Box 6645 0 Morgantown WV 26506-6645
lutlon
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APPENDIX B
Consent Form

ALTERNATIVES: If I do not participate in the study, the same drugs can be used to eliminate
pain. Not to participate in the study is an alternative.Other m dications that are standard for
pain relief include; aspirin and acetaminophen.
CONTACT PERSON:For more information about this research, I can contact Eric R. Menke,
at 304-293-0627. For more information regarding my rights as a research subject, I may contact
the Executive Secretary of the Institutional Review Board at 304-293-7073.If additional pain
medication is needed, I can contact Eric R. Menke at 304-293-0627.
CONFIDENTIALITY: I understand that any information about me obtained as a result of my
participation in this research will be kept as confidential as legally possible. I understand that my
research records, just like hospital records, may be subpoenaed by court order or may be
inspected by the sponsor or federal regulatory authorities, including the Food and Drug
Administration, without my additional consent. In any publications that result from this research,
neither my name or any information from which I might be identified will be published without
my consent.
VOLUNTARY PARTICIPATION: Participation in this study is voluntary. I understand that I
am free to withdraw my consent to participate in this study at any time.Refusal to participate or
withdraw will involve no penalty or loss of the benefits.I have been given the opportunity to ask
questions about the research, and I have received answers concerning areas I did not understand.
Upon signing this form, I will receive a copy.
I willingly consent to participate in this study.
Signature of Subject Date
Signature of Investigator Date
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APPENDIX C
Clinical Exam Form
Name: Phone # Patient # Tooth #
Patient History
Age:
Gender: Male Female
Allergies? Yes No If yes, what to?
Is the patient currently taking any medications?
If yes, what type and what for?
Yes No
Clinical Exam Cold Sensitive: + -
Hot Sensitive: + -
Spontaneous Pain: + -
Percussion Sensitive: + -
Sinus Tract: + -
Mobility: 0 1 2
Perio Pocket Depths: WNL Deep pocket at mm- -
Existing Restoration: Yes No
If yes, what kind?
Is the pulp chamber exposed? Yes No
Occlusion: Normal Hyper None
Diagnosis
Normal (RCT for Pro&)
1 Irreversible Pulpitis
_ Necrotic Pulp
PeriaDical
Normal
- Acute Apical Periodontitis
--   Chronic Apical Periodontitis
- Acute Apical Abscess
1 Chronic Apical Abscess
Phoenix Abscess
Treatment
Anesthetic Type:
Germicide:
Level of Instrumentation:
Pulp Chamber:
Amount: cc
Ideal Short Long
Dry chamber Blood Pus
Canal
Canal
Canal
Canal
Size
Size
Size
Size
Length_ _mm GG Profile
Length mm GG Profile
Length mm GG Profile
Length_ _m m  GG- Profile
Obterated? Yes N o
Filling Cement:
Filling Technic:
Filling Material:
Fill Evaluation: lmm from apex Past Apex Shorter than lmm from apex
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APPENDIX D
Pain Survey
Patient # Tooth # Date Time Started
Initial
Evaluation
Immediately
After RCT
4 Hrs Mer
None Pain so severe
you can’t stand it
None Pain so severe
you can’t stand it
None Pain so severe
you can’t stand it
Was additional pain medication required?Y s No At what time?
8 Hrs After None Pain so severe
you can’t stand it
Was additional pain medication required?Y s No At what time?
12 Hrs After None Pain so severe
you can’t stand it
Was additional pain medication required?Y s No At what time?
24 Hrs After None Pain so severe
you can’t stand it
Was additional pain medication required?Y s No At what time?
48 Hrs After None Pain so severe
you can’t stand it
Was additional pain medication required?Y s No At what time?
72 Hrs After None Pain so severe
you can’t stand it
Was additional pain medication required?Y s No At what time?
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APPENDIX E
Pulpal and Periapical Diagnosis Flow Charts
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APPENDIX F
Medication Schedule
Medication Schedule
Subject Medication
1 0
2 2
3 1
4 2
5 0
6 1
7 2
8 0
9 1
10 0
11 1
12 0
13 0
14 2
15 2
16 2
17 0
18 2
19 1
20 1
21 1
 0 = Placebo; 1= Ibuprofen; 2 = Etodolac
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ABSTRACT
THE EFFECTIVENESS OF PROPHYLACTIC ETODOLAC
ON POST-ENDODONTIC PAIN
By Eric R. Menke
The purpose of this clinical study was to determine if prophylactic oral
administration of etodolac would significantly reduce post-endodontic pain, when
compared to ibuprofen and a placebo.
Thirty-six patients requiring conventional root canal therapy were evaluated. 
Patients consented to single blind oral administration of either 400 mg of etodolac, 600
mg of ibuprofen, or a placebo, prior to conventional root canal therapy.  Pain evaluation
was completed on a pain survey that consisted of visual analog scales at the following
time intervals; initial, immediately after, 4 hours, 8 hours, 12 hours, 24 hours, 48 hours,
and 72 hours after initiation of root canal therapy.  Each patient was given an additional
dose of the test medication and was instructed to record the time it was taken, if
necessary, on the pain survey.
The results showed that a significant difference was found for ibuprofen’s ability
to reduce post-endodontic pain at 4 and 8 hours after initiation of root canal therapy,
when compared to etodolac and a placebo (4 Hours P-value = 0.0111; 8 Hours P-value =
0.0397).  A significant difference was also found for the periapical diagnosis and the need
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for additional medication after completion of root canal therapy.  A periapical diagnosis
of an Acute Apical Periodontitis or a Phoenix Abscess significantly required additional
medication after root canal therapy compared to a Normal Periapex, Chronic Apical
Periodontitis, and a Chronic Apical Abscess (P-value = 0.0077).
Two conclusion were found; 1) 600 mg of ibuprofen was superior to 400 mg of
etodolac and superior to a placebo for post-endodontic pain at 4 and 8 hours after
initiation of root canal therapy and 2) patients presenting with a periapical diagnosis of an
Acute Apical Periodontitis or a Phoenix Abscess are more likely to require additional
medication for post-endodontic pain compared to a periapical diagnosis of a Normal
Periapex, Chronic Apical Periodontitis, or a Chronic Apical Abscess.
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